These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 23879247)

  • 1. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions.
    Curry JL; Torres-Cabala CA; Kim KB; Tetzlaff MT; Duvic M; Tsai KY; Hong DS; Prieto VG
    Int J Dermatol; 2014 Mar; 53(3):376-84. PubMed ID: 23879247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
    Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
    Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
    Reyes-Habito CM; Roh EK
    J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
    Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
    Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
    Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous drug eruptions induced by sorafenib: a case series.
    Maddox JS; Kung EF; Petronic-Rosic V; Sethi A
    J Drugs Dermatol; 2008 Sep; 7(9):891-3. PubMed ID: 19112807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management.
    Manousaridis I; Mavridou S; Goerdt S; Leverkus M; Utikal J
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):11-8. PubMed ID: 22540151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy.
    Seervai RNH; Cho WC; Chu EY; Marques-Piubelli ML; Ledesma DA; Richards K; Heberton MM; Nelson KC; Nagarajan P; Torres-Cabala CA; Prieto VG; Curry JL
    J Cutan Pathol; 2022 Jan; 49(1):61-81. PubMed ID: 34622477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
    Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
    Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of EGFR inhibitor adverse events: a case series and treatment paradigm.
    Wnorowski AM; de Souza A; Chachoua A; Cohen DE
    Int J Dermatol; 2012 Feb; 51(2):223-32. PubMed ID: 22250636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
    Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
    Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.